New Malignant Pleural Mesothelioma Guidelines for Patients Available from NCCN
NCCN has released the NCCN Guidelines for Patients™: Malignant Pleural Mesothelioma, available free of charge on NCCN.com. NCCN Guidelines for Patients™ are a tool to help patients and their caregivers take a more active role in treatment decisions.
FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®), with the support of the NCCN Foundation, announces the latest addition to the library of NCCN Guidelines for Patients™, the NCCN Guidelines for Patients™: Malignant Pleural Mesothelioma. This resource is a patient-friendly, easy-to-understand translation of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Malignant Pleural Mesothelioma, which physicians use when determining appropriate cancer treatment. The NCCN Guidelines for Patients™ aim to help people with cancer and their loved ones discuss the best treatment options for them with their physicians.
The NCCN Guidelines for Patients™: Malignant Pleural Mesothelioma are supported by Baron & Budd, P.C., attorneys dedicated to protecting the rights of people who suffer from cancers like mesothelioma and lung cancer, which are often attributable to environmental toxins.
Mesothelioma is a rare cancer of the mesothelium, or the tissue that covers most organs inside the body, most commonly the lungs. It occurs in about 2,500 people in the United States every year. Although rare, mesothelioma is deadly, with about half of those diagnosed dying within one year. People diagnosed with mesothelioma have usually worked with asbestos approximately 20 to 40 years prior to diagnosis.
Baron & Budd is committed to helping people affected by asbestos-related cancers understand both their medical and legal options. We are honored to have sponsored this important resource for patients, said Russell Budd, president and managing shareholder of Baron & Budd.
Russell Budd is a member of the Board of the NCCN Foundation and has been a shareholder of Baron & Budd since 1985 and president and managing shareholder since 2002. Over the last decade, Mr. Budd has played a significant role in protecting the rights of people injured by exposure to asbestos.
In announcing the publication of the NCCN Guidelines for Patients™: Malignant Pleural Mesothelioma, NCCN`s CEO, William T. McGivney, PhD, acknowledged the importance of bringing this information to patients as rapidly as possible. The NCCN Foundation was created in no small way to help bring the best treatment guidelines to patients as effectively and quickly as possible, said Dr. McGivney. In this case, the Mesothelioma Guidelines for Patients were created from our professional version, reviewed by our experts, and ready for the public in slightly over three months. With generous support from donors like Baron & Budd, we can continue to provide authoritative information and recommendations to help patients and their families.
The NCCN Guidelines™ are developed by multidisciplinary panels of experts from NCCN Member Institutions and feature algorithms or decision trees that address every appropriate management option from initial work-up throughout the course of the disease. The NCCN Guidelines for Patients™ translate these professional guidelines in a clear, step-by-step manner that patients can use as the basis for making decisions and discussing treatment options with their physicians.
The NCCN Guidelines for Patients™ are available free of charge at NCCN.com, which, in addition, features informative articles for patients and caregivers. NCCN also offers seven other NCCN Guidelines for Patients™ including Breast, Non-Small Cell Lung, Ovarian and Prostate Cancers, Chronic Myelogenous Leukemia, Melanoma, and Multiple Myeloma. Additional NCCN Guidelines for Patients™ will be available throughout 2011. The NCCN Guidelines for Patients™: Malignant Pleural Mesothelioma will also be available on Baron and Budd`s dedicated mesothelioma website, Mesothelioma News.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 23 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. For more information, visit NCCN.org.
The NCCN Member Institutions are:
- Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center
- City of Hope Comprehensive Cancer Center
- Dana-Farber/Brigham and Women's Cancer Center
Massachusetts General Hospital Cancer Center
- Duke Cancer Institute
- Fox Chase Cancer Center
- Huntsman Cancer Institute at the University of Utah
- Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- Memorial Sloan-Kettering Cancer Center
- Moffitt Cancer Center
- The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
- Roswell Park Cancer Institute
- Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
- St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
- Stanford Cancer Institute
- University of Alabama at Birmingham Comprehensive Cancer Center
- UC San Diego Moores Cancer Center
- UCSF Helen Diller Family Comprehensive Cancer Center
- University of Colorado Cancer Center
- University of Michigan Comprehensive Cancer Center
- The University of Texas MD Anderson Cancer Center
- Vanderbilt-Ingram Cancer Center